CML burden monitoring via qRT-PCR was considered even before the advent of TKI (56, 57), but it was the unprecedented response to TKIs that pushed toward the implementation and standardization of the BCR-ABL1 assay. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.